Takeda Pharma net dips by 6.2%

Takeda Pharmaceutical Company of Japan has posted lower net profit of Yen 34 billion during the first quarter ended June 2014 as against Yen 36 billion in the corresponding period of last year due to stagnant sales, higher input costs and launch of new products in the US. Its revenue improved marginally by 0.2 per cent to Yen 411 billion from Yen 410 billion. Its earnings per share worked out to Yen 42.40 as compared to Yen 45.53 in the last period.

The company's sales of Ethical drugs improved only by 0.5 per cent to Yen 372 billion as its sales in Japan declined by 2.2 per cent to Yen 138 billion. Contribution from sales increase of products launched in and after 2010 such as Asilva and Nesina could not fully absorb the decrease in sales mainly due to the National Health Insurance price reduction and the penetration of generic products. However, its overseas sales improved by 2.7 per cent to Yen 234 billion due to higher sales of Velcade in the US and Pantoprazole in emerging markets including Asia.  

Takeda - Wipro strtegic partnership

Wipro Ltd., the information technology leader has entered into a  strategic partnership with Takeda Pharmaceutical Company Ltd., the largest pharmaceutical company in Japan and one of the global leaders of the industry.

The  strategic partnership will build advanced value in Takeda's operations by consolidating IT platforms across the organisation. As a strategic partner, Wipro will build and maintain an “as-a-service” global platform for Takeda that will drive synergies across its global entities through standardisation of IT architecture.

 Wipro will be primary provider of IT Infrastructure management services covering Takeda’s entities across the world, touching 30,000 users in 16 different languages, operating out of data centers in Asia, Europe and America.



According to Sangita Singh, chief executive Healthcare and Life Science Business Unit at Wipro, the partnership with Takeda is for a business transformation.  Wipro is leveraging its experience in enabling global pharma companies to achieve a leaner & standardized IT workplace and implement newer business models that put patient at the core. We look forward to collaboratively partnering with the Takeda team in enabling this unique platform across its global operations.